ampreloxetine
Phase 3Terminated 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Symptomatic Neurogenic Orthostatic Hypotension
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Trial Timeline
Sep 19, 2019 → Nov 12, 2021
NCT ID
NCT04095793About ampreloxetine
ampreloxetine is a phase 3 stage product being developed by Theravance Biopharma for Symptomatic Neurogenic Orthostatic Hypotension. The current trial status is terminated. This product is registered under clinical trial identifier NCT04095793. Target conditions include Symptomatic Neurogenic Orthostatic Hypotension.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04200573 | Phase 1 | Completed |
| NCT04095793 | Phase 3 | Terminated |
Competing Products
20 competing products in Symptomatic Neurogenic Orthostatic Hypotension
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sodium hyaluronate + placebo injection | Daiichi Sankyo | Phase 3 | 77 |
| ISV-305 | Sun Pharmaceutical | Phase 3 | 77 |
| rabeprazole sodium + Placebo | Eisai | Phase 3 | 77 |
| Verinurad + Febuxostat + Dapagliflozin | AstraZeneca | Phase 2 | 52 |
| RDEA3170 + Febuxostat + Benzbromarone | AstraZeneca | Phase 1/2 | 41 |
| Esomeprazole + Matching placebo | AstraZeneca | Phase 3 | 77 |
| DFV890 + Placebo | Novartis | Phase 2 | 52 |
| Omalizumab + Omalizumab + Placebo | Novartis | Phase 2 | 52 |
| Pasireotide + Octreotide | Novartis | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 2 | 52 |
| valsartan | Novartis | Approved | 85 |
| Atorvastatin - Cholestyramine - Sitosterol | Pfizer | Pre-clinical | 22 |
| Epoetin biosimilar | Pfizer | Pre-clinical | 22 |
| Apixaban + Standard of care | Pfizer | Phase 3 | 76 |
| Azithromycin plus chloroquine | Pfizer | Phase 3 | 76 |
| Mavacamten | Bristol Myers Squibb | Approved | 84 |
| Aficamten + Placebo | Sanofi | Phase 3 | 76 |
| Vandetanib 300 mg | Sanofi | Pre-clinical | 22 |
| REGN7508 + Acetylsalicylic Acid (ASA) + Placebo | Regeneron Pharmaceuticals | Phase 3 | 76 |
| Rivaroxaban + Placebo | Bayer | Phase 3 | 74 |